Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study.

ABSTRACT:

Background

Currently, there are two antifibrotics used to treat idiopathic pulmonary fibrosis (IPF): pirfenidone and nintedanib. Antifibrotics slow disease progression by reducing the annual decline of forced vital capacity (FVC), which possibly improves outcomes in IPF patients. During treatment, patients occasionally switch antifibrotic treatments. However, prognostic implication of changing antifibrotics has not yet been evaluated.

Methods

This multi-center retrospective cohort study examined 262 consecutive IPF patients who received antifibrotic therapy. Antifibrotic agents were switched in 37 patients (14.1%). The prognoses were compared between the patient cohort that switched antifibrotics (Switch-IPF) and those without (Non-Switch-IPF) using propensity-score matched

SUBMITTER: Suzuki Y 

PROVIDER: S-EPMC8274040 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature